Trials / Completed
CompletedNCT03925935
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Angiocrine Bioscience · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205 infusion following autologous stem cell transfusion on Day 0.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AB-205 | Engineered human umbilical vein endothelial cells |
Timeline
- Start date
- 2019-05-07
- Primary completion
- 2020-11-18
- Completion
- 2021-11-08
- First posted
- 2019-04-24
- Last updated
- 2022-03-03
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03925935. Inclusion in this directory is not an endorsement.